-+ 0.00%
-+ 0.00%
-+ 0.00%

INDEPENDENT STUDY PRESENTED AT AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING CONCLUDES REMESTEMCEL-L SUPERIOR TO RUXOLITINIB IN CLINICAL OUTCOMES AS TREATMENT FOR SR-AGVHD

路透·12/11/2025 23:22:27

登錄查看新聞詳情